Publications by authors named "S Hallmeyer"
Article Synopsis
- The purpose of the text is to provide guidance for various stakeholders in oncology regarding the medical use of cannabis and cannabinoids, including different forms and combinations.
- A systematic literature review was conducted on the efficacy and safety of cannabis for adults with cancer, involving multiple studies, but most outcomes showed low evidence certainty.
- The recommendations emphasize that while cannabis may help with specific symptoms like nausea from chemotherapy, its use as a cancer treatment should be in clinical trials, highlighting a need for further research.
Article Synopsis
- The OPTIMIzE registry study examined the effectiveness of immuno-oncology therapies in advanced melanoma by comparing outcomes of patients treated with anti-PD-1 monotherapy and a combination of nivolumab and ipilimumab.
- Patients receiving the combination therapy had a non-significantly lower risk of death and a higher disease control rate compared to those on monotherapy but experienced more severe side effects.
- Overall, the findings suggest that immuno-oncology treatments can be beneficial for patients with advanced melanoma, balancing effectiveness with potential adverse effects.
Objectives: The objective of this study is to explore the characteristics of the subset of patients with hematologic malignancies (HMs) who had little to no change in SARS-CoV-2 spike antibody index value levels after a third mRNA vaccine dose (3V) and to compare the cohort of patients who did and did not seroconvert post-3V to get a better understanding of the demographics and potential drivers of serostatus.
Study Design: This retrospective cohort study analyzed SARS-CoV-2 spike IgG antibody index values pre and post the 3V data on 625 patients diagnosed with HM across a large Midwestern United States healthcare system between 31 October 2019 and 31 January 2022.
Methods: To assess the association between individual characteristics and seroconversion status, patients were placed into two groups based on IgG antibody status pre and post the 3V dose, (-/+) and (-/-).
Background: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell death 1 (PD-1) antibody pembrolizumab. We report results from an open-label, single-arm, phase 1b study (NCT02307149) evaluating V937 plus the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab in patients with advanced melanoma.
Methods: Adult patients (aged ≥18 years) with histologically confirmed metastatic or unresectable stage IIIB/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3 mg/kg Q3W administered for four doses starting on day 22.
Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics.
Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus.